SCHEMBL14710936

SCHEMBL14710936

COC(=O)Cc1ccc(C2CCN(C(=O)CNC(=O)OCc3ccccc3)CC2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 4/20 0.51
HTT P42858 1/20 0.50
MCHR1 Q99705 1/20 0.49
PREP P48147 2/20 0.48
ALDH1A1 P00352 3/20 0.47
RAB9A P51151 2/20 0.47
LMNA P02545 1/20 0.47
POLB P06746 1/20 0.46
F13A1 P00488 1/20 0.44
TGM2 P21980 1/20 0.44
TGM1 P22735 1/20 0.44
ENPP2 Q13822 1/20 0.43
NPC1 O15118 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TPSAB1 Q15661 1/20 0.42
TPSD1 Q9BZJ3 1/20 0.42
TPSG1 Q9NRR2 1/20 0.42
KDM1A O60341 1/20 0.42
RCOR1 Q9UKL0 1/20 0.42
FNTA P49354 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14710869 0.90 CCR1 (0.49) CCR1HTTMCHR1ALDH1A1RAB9A
SCHEMBL14711122 0.89 HTT (0.49) CCR1HTTMCHR1PREPALDH1A1
SCHEMBL14790773 0.88 PREP (0.49) CCR1HTTMCHR1PREPALDH1A1
SCHEMBL6747802 0.85 HTT (0.61) CCR1HTTALDH1A1RAB9ALMNA
SCHEMBL14711221 0.82 CCR1 (0.64) CCR1PREPF13A1TGM2TGM1
SCHEMBL14711120 0.82 ALDH1A1 (0.45) CCR1HTTALDH1A1RAB9ALMNA
SCHEMBL14711124 0.82 CCR1 (0.64) CCR1PREPF13A1TGM2TGM1
SCHEMBL14711222 0.81 CCR1 (0.59) CCR1HTTALDH1A1POLBF13A1
SCHEMBL14711037 0.81 CCR1 (0.59) CCR1ALDH1A1F13A1TGM2TGM1
SCHEMBL14710994 0.81 CCR1 (0.59) CCR1HTTALDH1A1POLBF13A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-8975235-B2 Lysophosphatidic acid receptor antagonists INTERMUNE, INC. (US) 2015-03-10 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-03-21 US disclosed
WO-2013025733-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS INTERMUNE, INC. (US) 2013-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072449-A1 LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS LPAR1, LPAR2, LPAR5 CCR1 1107/4885HTT 3090/4885MCHR1 748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.